Evaluation of dosing time-related anti-hypertensive efficacy of valsartan in patients with type 2 diabetes

Clinical and Experimental Hypertension

Volumn 33, Issue 1, 2011, Pages 56-62

  Suzuki, Katsunori ^a   Aizawa, Yoshifusa ^b  

^a Saiseikai Niigata Daini Hospital   (Japan)

^b NIIGATA UNIVERSITY GRADUATE SCHOOL OF MEDICAL AND DENTAL SCIENCES   (Japan)

Author keywords

anti hypertensive therapy; dose timing; morning hypertension; urinary albumin excretion; valsartan

Indexed keywords

ALBUMIN; CREATININE; VALSARTAN;

ADULT; ARTICLE; BLOOD PRESSURE MONITORING; BLOOD PRESSURE REGULATION; CHRONOTHERAPY; CLINICAL ARTICLE; CREATININE BLOOD LEVEL; CREATININE URINE LEVEL; CROSSOVER PROCEDURE; DIABETIC NEPHROPATHY; DIASTOLIC BLOOD PRESSURE; DIZZINESS; DOSAGE SCHEDULE COMPARISON; DRUG DOSE REGIMEN; DRUG EFFICACY; EVENING DOSAGE; FEMALE; HOME MONITORING; HUMAN; HYPERTENSION; ISCHEMIC HEART DISEASE; MALE; MORNING DOSAGE; NON INSULIN DEPENDENT DIABETES MELLITUS; ORTHOSTATIC HYPOTENSION; RANDOMIZED CONTROLLED TRIAL; SYSTOLIC BLOOD PRESSURE;

AGED; ANTIHYPERTENSIVE AGENTS; BLOOD PRESSURE; CIRCADIAN RHYTHM; DIABETIC NEPHROPATHIES; DOSE-RESPONSE RELATIONSHIP, DRUG; DRUG ADMINISTRATION SCHEDULE; FEMALE; HUMANS; HYPERTENSION; MALE; MIDDLE AGED; TETRAZOLES; TIME FACTORS; TREATMENT OUTCOME; VALINE;

EID: 79251493834     PISSN: 10641963     EISSN: 15256006     Source Type: Journal    
DOI: 10.3109/10641963.2010.503306     Document Type: Article

References (27)

1. Gu K, Cowie CC, Harris MI. Diabetes and decline in heart disease mortality in US adults. JAMA 1999;281:1291-1297.
2. UK Prospective Diabetes Study Group. Tight blood pressure control and risk of macrovascular and microvascular complica-tions in type 2 diabetes: UKPDS 38. BMJ 1998;317:703-713.
3. Leehey DJ, Singh AK, Alavi N, Singh R. Role of angiotensin II in diabetic nephropathy. Kidney Int Suppl 2000;77:S93-S98.
4. Committee for the Guidelines for the Management of Hypertension, Japanese Society of Hypertension, (Eds.). Guidelines for the Management of Hypertension in 2009. Tokyo: Life Science Publishing, 2009.
5. Millar-Craig MW, Bishop CN, Raftery EB. Circadian variation of blood-pressure. Lancet 1978;1:795-797.
6. Bobrie G, Chatellier G, Genes N, Clerson P, Vaur L, Vaisse B, Menard J, Mallion JM. Cardiovascular prognosis of "masked hypertension" detected by blood pressure self-measurement in elderly treated hypertensive patients. JAMA 2004;291:1342-1349.
7. Elliott WJ. Cyclic and circadian variations in cardiovascular events. Am J Hypertens 2001;14:291S-295S
8. Portaluppi F, Bagni B, degli Uberti E, Montanari L, Cavallini R, Trasforini G, Margutti A, Ferlini M, Zanella M, Parti M. Circadian rhythms of atrial natriuretic peptide, rennin, aldos-terone, cortisol, blood pressure and heart rate in normal and hypertensive subjects. J Hypertens 1990;8:85-95.
9. Kala R, Fyhrquist F, Eisalo A. Diurnal variation of plasma angio-tensin II in man. Scand J Clin Lab Invest 1973;31:363-365.
10. Staessen JA, Wang JG, Thijs L. Cardiovascular protection and blood pressure reduction: a meta-analysis. Lancet 2001;358: 1305-1315.
11. Blood Pressure Lowering Treatment Trialists' Collaboration. Effects of different blood-pressure-lowering regimens on major cardiovascular events: results of prospectively-designed over-views of randomized trials. Lancet 2003;362:1527-1535.
12. Law MR, Wald NJ, Morris JK, Jordan RE. Value of low dose combination treatment with blood pressure lowering drugs: Analysis of 354 randomised trials. BMJ 2003; 326:1427-1431.
13. Kario K. Clinician's Manual on Early Morning Risk Manage-ment in Hypertension. London: Science Press, 2004; pp 1-68.
14. Tei M, Uebaba K. Phase I clinical study of angiotensin II receptor antagonist CGP48933 (Valsartan)-Multiple dose study. J Clin Ther Med 1998;14:1727-1743 (in Japanese).
15. Hermida RC, Calvo C, Ayala DE, Mojón A, Rodríguez M, Chayán L, López JE, Fontao MJ, Soler R, Fernández JR. Administration time-dependent effects of valsartan on ambu-latory blood pressure in elderly hypertensive subjects. Chronobiol Int 2005;22:755-776.
16. Ohta M. Clinical efficacy of valsartan depending on dose and dosing frequency. J New Rem & Clin 2006;55:1149-1154 (in Japanese).
17. Hirose K, Nakajima T. Evaluation of efficacy of different valsartan regimens using home blood pressure. Ther Res 2009;30:1235-1243 (in Japanese).
18. Yamagishi T. Efficacy of ARB valsartan at a dose of 160 mg-Evaluation of efficacy for home blood pressure in refractory hypertension. Blood Pressure 2005;12:883-893 (in Japanese).
19. Kasayuki N. Evaluation of antihypertensive efficacy of valsar-tan at increased doses. J New Rem & Clin 2007;56:668-674 (in Japanese).
20. Physicians' Desk Reference. 63rd ed. Physicians Desk Reference Inc 2009.
21. Bremner AD, Baur M, Oddou-Stock P, Bodin F. Valsartan: long-term efficacy and tolerability compared to lisinopril in elderly patients with essential hypertension. Clin Exp Hypertens 1997;19:1263-1285.
22. Kang JJ, Toma I, Sipos A, Meer EJ, Vargas SL, Peti-Peterdi J. The collecting duct is the major source of prorenin in diabetes. Hypertension 2008;51:1597-1604.
23. Nguyen G, Delarue F, Burcklé C, Bouzhir L, Giller T, Sraer JD. Pivotal role of the renin/prorenin receptor in angiotensin II production and cellular responses to renin. J Clin Invest 2002;109:1417-1427.
24. Lurbe E, Redon J, Kesani A, Pascual JM, Tacons J, Alvarez V, Batlle D. Increase in nocturnal blood pressure and progression to microalbuminuria in type 1 diabetes. N Engl J Med 2002;347:797-805.
25. Hermida RC, Calvo C, Ayala DE, López JE. Decrease in urinary albumin excretion associated with the normalization of nocturnal blood pressure in hypertensive subjects. Hypertension 2005;46:960-968.
26. Mochizuki S, Dahlöf B, Shimizu M, Ikewaki K, Yoshikawa M, Taniguchi I, Ohta M, Yamada T, Ogawa K, Kanae K, Kawai M, Seki S, Okazaki F, Taniguchi M, Yoshida S, Tajima N; Jikei Heart Study group. Valsartan in a Japanese population with hypertension and other cardiovascular disease (Jikei Heart Study): a randomised, open-label, blinded endpoint morbidity-mortality study. Lancet 2007;28:1431-1439.
27. Sawada T, Yamada H, Dahlöf B, Matsubara H; KYOTO HEART Study Group. Effects of valsartan on morbidity and mortality in uncontrolled hypertensive patients with high car-diovascular risks: KYOTO HEART Study. Eur Heart J 2009;30:2461-2469.